A9T-1101

N/A

Report date: 2025/11/26 17:11:31
NME

Base Information

Drug NameA9T-1101
Drug Alias NameA9T-110118F-AmBF3-TATE PET/CT18F-AMBF3-TATE
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Fluorine > 18F +[5] 
Mechanisms of ActionPositron-emission tomography enhancersEmission-computed tomography enhancers
TargetsUpdating
Therapy Area/IndicationsNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlpha-9 Oncology IncThe University Of British Columbia
China Registration ClassN/A

Develop Information

Active CompaniesBritish Columbia Cancer Agency
Inactive CompaniesN/A
Active IndicationsNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A